Merck to Acquire ArQule, Advancing Leadership in Oncology
Acquisition Further Diversifies Merck’s Oncology Pipeline with Expansion into Targeted Therapies That Treat Hematological Malignancies
KENILWORTH, N.J. & BURLINGTON, Mass.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and ArQule, Inc. (Nasdaq: ARQL) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire ArQule for $20 per share in cash for an approximate total equity value of $2.7 billion. ArQule is a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases.
Merck Media:
Pam Eisele
(267) 305-3558
Ayn Wisler
(917) 691-6218
ArQule Media:
Cait Williamson, Ph.D.
(646) 751-4366
Merck Investors:
Peter Dannenbaum
(908) 740-1037
Courtney Ronaldo
(908) 740-6132
ArQule Investors:
Marc Schegerin, M.D.
(781) 994-0300
Read Original Article: Merck to Acquire ArQule, Advancing Leadership in Oncology »
